4.7 Article

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 13, 页码 6531-6546

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00760

关键词

-

资金

  1. National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases
  2. National Institute of Child Health and Human Development of the National Institutes of Health [R01GM086858, R01AI089441, R01AI111341, R01HD080670]
  3. United States Department of Agriculture [2014-06183]
  4. United States Department of Veterans Affairs Biomedical Laboratory Research and Development [BX002440]
  5. Stanley Medical Research Institute [07R1857]
  6. U.S. Department of Energy Office of Basic Energy Sciences [DE-AC02-76SF00515]
  7. National Institutes of Health [P41GM103393]

向作者/读者索取更多资源

New therapies are needed for the treatment of toxoplasmosis, which is a disease caused by the protozoan parasite Toxoplasma gondii. To this end, we previously developed a potent and selective inhibitor (compound 1) of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) that possesses antitoxoplasmosis activity in vitro and in vivo. Unfortunately, 1 has potent human ether-a-go-go-related gene (hERG) inhibitory activity, associated with long Q-T syndrome, and consequently presents a cardiotoxicity risk. Here, we describe the identification of an optimized TgCDPK1 inhibitor 32, which does not have a hERG liability and possesses a favorable pharmacokinetic profile in small and large animals. 32 is CNS-penetrant and highly effective in acute and latent mouse models of T. gondii infection, significantly reducing the amount of parasite in the brain, spleen, and peritoneal fluid and reducing brain cysts by >85%. These properties make 32 a promising lead for the development of a new antitoxoplasmosis therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor in Neospora caninum and Danio rerio

Joachim Muller, Nicoleta Anghel, Dennis Imhof, Kai Hanggeli, Anne-Christine Uldry, Sophie Braga-Lagache, Manfred Heller, Kayode K. Ojo, Luis-Miguel Ortega-Mora, Wesley C. Van Voorhis, Andrew Hemphill

Summary: Neospora caninum, closely related to Toxoplasma gondii, is a parasite that can cause fetal malformations in livestock. The development of calcium-dependent protein kinase 1 inhibitors has shown promise in treating neosporosis. However, some of these inhibitors have adverse effects on fertility in pregnant mouse models and cause embryonic malformations in zebrafish models. Through affinity chromatography and mass spectrometry, it has been found that BKI-1748 interacts not only with specific targets in apicomplexans but also with targets in other eukaryotes, indicating involvement in common essential pathways.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Microbiology

Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy

Samantha A. Michaels, Matthew A. Hulverson, Grant R. Whitman, Linh T. Tran, Ryan Choi, Erkang Fan, Case W. McNamara, Melissa S. Love, Kayode K. Ojo

Summary: A phenotypic screen of the ReFRAME compound library identified Mavelertinib as a potential therapeutic for giardiasis. It showed efficacy against metronidazole-resistant strains and demonstrated good results in a mouse model.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Article Veterinary Sciences

Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes-Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice

Dennis Imhof, William Robert Pownall, Carling Schlange, Camille Monney, Luis-Miguel Ortega-Mora, Kayode K. Ojo, Wesley C. Van Voorhis, Anna Oevermann, Andrew Hemphill

Summary: This study investigated the safety and efficacy of a combined vaccination-drug treatment approach in a pregnant neosporosis mouse model. The results showed that the combination treatment was more effective in reducing infection and improving pup survival compared to vaccination or drug treatment alone. Further evaluation is recommended.

FRONTIERS IN VETERINARY SCIENCE (2022)

Article Chemistry, Medicinal

7H-Pyrrolo[2,3-d]pyrimidine-4-amines as Potential Inhibitors of Plasmodium falciparum Calcium-Dependent Protein Kinases

Tswene D. Seanego, Hlamulo E. Chavalala, Hendrik H. Henning, Charles B. de Koning, Heinrich C. Hoppe, Kayode K. Ojo, Amanda L. Rousseau

Summary: A series of pyrrolo[2,3-d]pyrimidines were designed and evaluated in vitro for their inhibitory activity against PfCDPK4 and PfCDPK1. Four compounds exhibited promising inhibitory activity.

CHEMMEDCHEM (2022)

Article Biochemistry & Molecular Biology

Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics

Carrie S. Tambo, Sarvind Tripathi, B. Gayani K. Perera, Dustin J. Maly, Alexander J. Bridges, Gert Kiss, Seth M. Rubin

Summary: Cyclin-dependent kinases (CDKs) are crucial regulators of cell proliferation and have been studied as potential targets for cancer therapy. The interaction between CDKs and cyclins, their activators, plays a central role in cell cycle progression. In this study, a biolayer interferometry assay was used to quantify CDK-cyclin binding interactions. The results showed that Type I inhibitors increase the affinity between CDK2 and cyclin A by slowing down cyclin dissociation, while Type II inhibitors and other small-molecule CDK2 binders have different effects on cyclin association and dissociation kinetics, leading to decreased affinity. The findings suggest that the plasticity of the CDK2 active site contributes to the differential impact of small molecules on cyclin binding kinetics.

ACS CHEMICAL BIOLOGY (2023)

Article Biochemistry & Molecular Biology

Photoswitchable Inhibitors to Optically Control Specific Kinase Activity

Tim Aguirre, Ellen Teichmann, Florian Q. Roempp, Ruthey Vivier, Cole Bryant, Matthew A. Hulverson, Wesley C. Van Voorhis, Kayode K. Ojo, J. Stone Doggett, Dorothea Fiedler, Stefan Hecht

Summary: This study developed photoswitchable azopyrazoles as inhibitors to selectively target CDPK1 from Toxoplasma gondii. The inhibitory activity of CDPK1 is dependent on the size of the gatekeeper residue. The photoswitchable inhibitors also showed activity against T. gondii and Cryptosporidium parvum infections in a cell culture model.

ACS CHEMICAL BIOLOGY (2023)

Article Microbiology

Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis

Matthew A. Hulverson, Ryan Choi, Deborah A. Schaefer, Dana P. Betzer, Molly C. McCloskey, Grant R. Whitman, Wenlin Huang, Sangun Lee, Andy Pranata, Malcolm D. McLeod, Kennan C. Marsh, Dale J. Kempf, Bruce E. LeRoy, Mark T. Zafiratos, Aimee L. Bielinski, Robert C. Hackman, Kayode K. Ojo, Samuel L. M. Arnold, Lynn K. Barrett, Saul Tzipori, Michael W. Riggs, Erkang Fan, Wesley C. Van Voorhis

Summary: Recent advances in the development of bumped kinase inhibitors for treating cryptosporidiosis have focused on a specific structure known as 5-aminopyrazole-4-carboxamide scaffold, which has shown superior efficacy, reduced hERG inhibition, and excellent safety profiles in vitro. Three compounds (BKI-1770, -1841, and -1708) demonstrated strong effectiveness in mice infected with C. parvum. While BKI-1770 and BKI-1841 were effective in a C. parvum calf model, they caused limb hyperflexion. Toxicity experiments in rats and calves revealed bone toxicity at slightly higher doses than the efficacious dose for BKI-1770. Both BKI-1770 and BKI-1841 showed neurological effects in mice, and BKI-1770 also displayed bone toxicity. However, BKI-1708 showed no signs of bone toxicity or neurological effects in mice, making it a promising candidate for further evaluation.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Plant Sciences

Appraisal of Fungus-Derived Xanthoquinodins as Broad-Spectrum Anti-Infectives Targeting Phylogenetically Diverse Human Pathogens

Jin Woo Lee, Jennifer E. E. Collins, Matthew A. A. Hulverson, Laarni Kendra T. Aguila, Caroline M. M. Kim, Karen L. L. Wendt, Debopam Chakrabarti, Kayode K. K. Ojo, Gwendolyn E. E. Wood, Wesley C. C. Van Voorhis, Robert H. H. Cichewicz

Summary: Xanthoquinodins are a unique class of compounds found in several fungal species, and they have been reported as secondary metabolites. A fungal extract from Trichocladium sp. was found to have strong inhibitory effects against several human pathogens. Six new compounds and several previously reported natural products were identified through purification and analysis. Among them, Xanthoquinodins A1 and A2 showed the most promising broad-spectrum inhibitory effects against multiple human pathogens.

JOURNAL OF NATURAL PRODUCTS (2023)

Article Biochemistry & Molecular Biology

A chemically controlled Cas9 switch enables temporal modulation of diverse effectors

Cindy T. T. Wei, Nicholas A. A. Popp, Omri Peleg, Rachel L. L. Powell, Elhanan Borenstein, Dustin J. J. Maly, Douglas M. M. Fowler

Summary: Researchers have developed a chemically activated DNA-binding Cas9 switch called ciCas9, which enables temporal control over seven Cas9 effectors including base editors and transcriptional activators. Using this switch, they analyzed the kinetics of base editing and found that editing occurs within hours and early rapid editing predicts the final editing magnitude. They also discovered that editing at preferred nucleotides increases bystander edits. The ciCas9 switch offers a versatile approach for generating chemically controlled Cas9 effectors and enables precise temporal effector control for kinetic studies.

NATURE CHEMICAL BIOLOGY (2023)

Article Virology

Detection of SARS-CoV-2 in Terrestrial Animals in Southern Nigeria: Potential Cases of Reverse Zoonosis

Anise N. N. Happi, Akeemat O. O. Ayinla, Olusola A. A. Ogunsanya, Ayotunde E. E. Sijuwola, Femi M. M. Saibu, Kazeem Akano, Uwem E. E. George, Adebayo E. E. Sopeju, Peter M. M. Rabinowitz, Kayode K. K. Ojo, Lynn K. K. Barrett, Wesley C. C. Van Voorhis, Christian T. T. Happi

Summary: This study investigated the presence of SARS-CoV-2 in various animals in Nigeria and found that the virus can infect multiple animal species, including poultry, pigs, domestic ruminants, and lizards. This highlights the ability of SARS-CoV-2 to spread among animals and emphasizes the importance of continuous monitoring and intervention.

VIRUSES-BASEL (2023)

Article Microbiology

Identification of Fungus-Derived Natural Products as New Antigiardial Scaffolds

Matthew A. Hulverson, Samantha A. Michaels, Jin Woo Lee, Karen L. Wendt, Linh T. Tran, Ryan Choi, Wesley C. Van Voorhis, Robert H. Cichewicz, Kayode K. Ojo

Summary: In this study, natural products and fungal extracts were screened for their ability to inhibit the growth of Giardia lamblia, leading to the discovery of novel chemical scaffolds that can potentially be developed into effective antigiardial agents.

MICROBIOLOGY SPECTRUM (2023)

Article Chemistry, Medicinal

Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development

Michael K. Fenwick, Alexandra R. Reers, Yi Liu, Rachael Zigweid, Banumathi Sankaran, Janis Shin, Matthew A. Hulverson, Bradley Hammerson, Elena Fernandez Alvaro, Peter J. Myler, Alexis Kaushansky, Wesley C. Van Voorhis, Erkang Fan, Bart L. Staker

Summary: Two potential hit compounds were identified that could be effective against Cryptosporidium, and their interaction with CpNMT was validated, providing insights for identifying drug targets for treating protozoan parasite infections.

ACS INFECTIOUS DISEASES (2023)

暂无数据